Focus on Oncology
At Genentech, we take a rigorous, comprehensive approach to understanding cancer biology and drug discovery.
Our scientists are leaders in the identification of novel cell surface molecules and are working to characterize tumor antigens that may be useful in fighting various forms of cancer. These tumor antigens are used to produce sophisticated monoclonal antibodies that selectively target the desired cancer to modulate function, mark cells for destruction by the immune system, or precisely deliver lethal doses of cytotoxic compounds.
We continue to expand our expertise in angiogenesis and apoptosis - discovering new basic insights and new therapeutic opportunities. Our major research programs also include unraveling complex signaling pathways, and targeting critical aspects of the cell cycle, metabolic regulators, and the immune response to cancer. Cancer stem cells are also rapidly becoming topics of exceptional excitement and opportunity.
Publication: Nature, July 2012
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.
A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies.